Loading clinical trials...
Loading clinical trials...
A Perspective and Multicenter Phase II Trial of Tirelizumab Combined With R2-ICE Regimen (Rituximab, Lenalidomide, Ifosfamide, Carboplatin, Etoposide) in the Treatment of Refractory or Relapse DLBCL or HGBL
Conditions
Interventions
TR2-ICE
Locations
1
China
Hospital 307
Beijing, Beijing Municipality, China
Start Date
August 1, 2021
Primary Completion Date
July 30, 2022
Completion Date
July 30, 2023
Last Updated
September 20, 2021
Lead Sponsor
Affiliated Hospital to Academy of Military Medical Sciences
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions